Fox Run Management, L.L.C. Arcutis Biotherapeutics, Inc. Transaction History
Fox Run Management, L.L.C.
- $433 Million
- Q3 2024
A detailed history of Fox Run Management, L.L.C. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 19,330 shares of ARQT stock, worth $289,756. This represents 0.04% of its overall portfolio holdings.
Number of Shares
19,330
Previous 28,839
32.97%
Holding current value
$289,756
Previous $268,000
33.21%
% of portfolio
0.04%
Previous 0.05%
Shares
3 transactions
Others Institutions Holding ARQT
# of Institutions
197Shares Held
129MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC11.7MShares$175 Million0.07% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$164 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$161 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$132 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$129 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $902M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...